Publications:230
Eimear E Kenny, PhD
About Me
Dr. Eimear Kenny, PhD, is a Professor of Medicine and Genetics, and the Founding Director of the Institute for Genomic Health. She leads research at the interface of genomics, medicine, and computer science. She uses data science and massive-scale databases of genomic information to improve human health. Her research spans several different areas, including population and statistical genetics; machine-learning approaches for genomic discovery for rare and common diseases; genomic risk prediction for preventive health; clinical trials in genomic medicine; and digital app development for precision medicine. Her goal is to lead a new paradigm for genomic research embedded in health systems and to enable genomic medicine on a global scale. She is a scientific advisor to many initiatives in government, non-profit and industry arenas.
Language
English
Position
DIRECTOR, INSTITUTE FOR GENOMIC HEALTH, PROFESSOR | Medicine, General Internal Medicine, PROFESSOR | Genetics and Genomic Sciences
Research Topics
Genetics, Genomics
Multi-Disciplinary Training Areas
Disease Mechanisms and Therapeutics (DMT), Neuroscience [NEU]
Video
Education
BSc, Trinity College Dublin
MSc, University of Leeds
PhD, Rockefeller University
Post-doc, Stanford University
Publications
Selected Publications
- Using the linear references from the pangenome to discover missing autism variants. Yang Sui, Jiadong Lin, Michelle D. Noyes, Youngjun Kwon, Isaac Wong, Nidhi Koundinya, William T. Harvey, Mei Wu, Kendra Hoekzema, Katherine M. Munson, Gage H. Garcia, Jordan Knuth, Julie Wertz, Tianyun Wang, Kelsey Hennick, Druha Karunakaran, Rafael A. Polo Prieto, Rebecca Meyer-Schuman, Fisher Cherry, Davut Pehlivan, Bernhard Suter, Jonas A. Gustafson, Danny E. Miller, Giulia Zunino, Xiaoyu Zhuo, Ying Zhou, Wenjin Zhang, Dong Ahn Yoo, Kai Ye, Zheng Xu, Zilan Xin, Conor V. Whelan, Aaron M. Wenger, Ting Wang, Lisa E. Wang, Charles Wang, Brian P. Walenz, Mitchell R. Vollger, Ivo Violich, Flavia Villani, Rahul Varki, Matteo Tommaso Ungaro, Mohammed Uddin, Francesca Floriana Tricomi, Chad Tomlinson, Jack A.S. Tierney, Ahmad Abou Tayoun, Arda Söylev, Eimear E. Kenny, Katherine E. Bonini. Nature Communications
- Association of high and moderate penetrance monogenic variants, polygenic risk, and family history with breast cancer in an ancestrally diverse population. Emily R. Soper, Nicole A. Casasanta, Bethany Dubois, Gillian M. Belbin, Eimear E. Kenny, Noura S. Abul-Husn. Cancer genetics
- Global multi-ancestry genome-wide analyses identify genes and biological pathways associated with thyroid cancer and benign thyroid diseases. Samantha L. White, Maizy S. Brasher, Jack Pattee, Wei Zhou, Sinéad Chapman, Yon Ho Jee, Caitlin C. Bell, Taylor L. Jamil, Martin Barrio, Christopher H. Arehart, Luke M. Evans, Jibril Hirbo, Nancy J. Cox, Peter Straub, Shinichi Namba, Emily Bertucci-Richter, Lindsay Guare, Ahmed Edris, Sam Morris, Ashley J. Mulford, Haoyu Zhang, Brian Fennessy, Martin D. Tobin, Jing Chen, Alexander T. Williams, Catherine John, David A. van Heel, Rohini Mathur, Sarah Finer, Marta R. Moksnes, Ben M. Brumpton, Bjørn Olav Åsvold, Raitis Peculis, Vita Rovite, Ilze Konrade, Ying Wang, Kristy Crooks, Sameer Chavan, Matthew J. Fisher, Nicholas Rafaels, Meng Lin, Jonathan A. Shortt, Alan R. Sanders, David C. Whiteman, Stuart MacGregor, Sarah E. Medland, Unnur Thorsteinsdóttir, Kári Stefánsson, Michael H. Preuss, Eimear Kenny. Nature Genetics
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Kenny during 2025 and/or 2026. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Board Service
- Overtone
- Galateo Bio
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
- Galateo Bio
Mount Sinai’s faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.